SEC Filing · 6-K
NervGen Pharma Corp.
NGENNASDAQEQUITYCurrent
SEC Filing
Company context
NervGen (NASDAQ: NGEN) is a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. The Company’s mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. NervGen’s lead therapeutic candidate, NVG-291, is a subcutaneously administered neuroreparative peptide designed to counteract the inhibitory effects of chondroitin sulfate proteoglycans. NVG-291 has received Breakthrough Therapy designation from the FDA for the treatment of chronic traumatic cervical motor-incomplete SCI, based on preliminary clinical evidence from the Phase 1b/2a CONNECT SCI study indicating the potential for substantial improvement over available therapy on one or more clinically significant endpoints. NVG-291 has also received FDA Fast Track designation and Orphan Drug designation from the European Medicines Agency for the treatment of SCI. For more information, visit www.nervgen.com and follow NervGen on X and LinkedIn.